Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies |
The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD |
Reach Grants |
2018 |
Maryland |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma
|
Beckman Research Institute of City of Hope / Margarita Gutova, MD |
Reach Grants |
2013 |
California |
Moving EphB4 Therapeutics to Pediatric Phase I/II Trials |
Oregon Health & Science University / Charles Keller, MD |
Reach Grants |
2013 |
Oregon |
Optimizing TCRαβ+/CD19+-depleted haploidentical HSCT for ALL using donor-derived genome-edited CAR T cells |
Stanford University School of Medicine / Alice Bertaina, MD/PhD |
Reach Grants |
2019 |
California |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma |
Baylor College of Medicine / Cliona Rooney, PhD |
Reach Grants |
2013 |
Texas |
Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors |
Dana-Farber Cancer Institute / Loren Walensky, MD/PhD |
Reach Grants |
2021 |
Massachusetts |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Enhancing TKI Therapy in Ph-Like Leukemia |
The Regents of the University of California, Irvine / David Fruman, PhD |
Reach Grants |
2022 |
California |
Multivalent Nanomedicine to Treat High-Risk Pediatric Solid Tumors |
Children’s Hospital of Philadelphia / Garrett Brodeur, MD |
Reach Grants |
2019 |
Pennsylvania |
DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma |
Children’s Hospital of Philadelphia / Michael Hogarty, MD |
Reach Grants |
2016 |
Pennsylvania |